瑞典男孩及年轻男性HPV补种疫苗的成本效果分析
该研究用动态马尔可夫多状态模型评估瑞典未接种HPV疫苗的青少年男孩及年轻男性补种的成本效果,与不接种相比。补种可减少HPV相关癌症,17-26岁组每获得QALY成本为EUR 42,800,可视为物有所值,结果对疫苗效力和价格敏感。
要点
- 17-26岁男孩补种HPV疫苗每获得QALY成本EUR 42,800,在瑞典可视为物有所值。
- 补种通过直接和群体免疫间接效应减少男女HPV相关癌症。
- 结果对疫苗效力和疫苗价格敏感,暴露前接种效力更高。
核心结论
- 为17-26岁青少年男孩及年轻男性提供HPV补种疫苗在瑞典可视为物有所值。
研究设计与样本
- 动态马尔可夫多状态模型模拟瑞典HPV相关癌症负担及补种效果,比较补种与不接种。
- 模型考虑接种者预防癌症的直接效应和群体免疫的间接效应。
- 成本包括HPV相关癌症资源使用、患病生产力损失及疫苗和接种费用,健康效应以QALY衡量。
主要发现
- 为17-19岁男孩出生队列补种在模拟时间范围内减少约510例HPV相关癌症。
- 17-26岁和17-30岁对应减少例数分别为1450和2080。
- 每获得QALY成本:17-19岁EUR 50,100,17-26岁EUR 42,800,17-30岁EUR 32,800。
- 结果对疫苗效力和疫苗价格变化敏感。
临床怎么用
- 在瑞典环境下,可考虑为17-26岁未接种HPV疫苗的青少年男孩及年轻男性提供补种。
- 决策需结合疫苗效力和价格变动进行敏感性评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The aim of the study was to assess the cost-effectiveness of a catch-up vaccination against HPV of unvaccinated adolescent boys and young men in Sweden. Costs and health effects of HPV related cancer in such situation was compared to no vaccination of the same cohort. We used a dynamic Markov multi-state model to simulate the burden of HPV related cancer in Sweden and the effects of a catch-up vaccination in adolescent boys and young men compared to no vaccination. The model accounted for direct effects of preventing cancer in vaccinated individuals and indirect effects of vaccination through herd-immunity. The main epidemilogical outcome was the number of HPV related cancers in men and women. Costs included resource use for HPV related cancer, production loss when sick, and the cost of the vaccine and administration. Health effects were measured as quality-adjusted life years (QALY). Costs and QALYs were accumulated over the simulated time-horizon to calculate the cost per gained QALY. A HPV catch-up vaccination strategy for adolescents boys and young men would lead to a reduction in the number of HPV related cancers, both through direct and indirect effects. Vaccinating a birth cohort of boys aged 17-19 would lead to a reduction of about 510 cases of HPV related cancer over the simulated time-horizon. The corresponding figures for ages 17-26 and 17-30 were 1450 and 2080 respectively. The cost per gained QALY was EUR 50,100 for 17-19, EUR 42,800 for 17-26, and EUR 32,800 for 17-30 years old. Providing catch up vaccination to adolescent boys and young men aged 17-26 years old can be considered good value for money in a Swedish setting. The results are sensitive to changes in the vaccine effectiveness, which is greater before being exposed to the virus, and to the price of the vaccine.
引用
- Wolff E, Schollin Ask L, Larsson S, et al. Cost-effectiveness analyses of catch-up vaccination against human papillomavirus (HPV) related cancers of boys and young men in Sweden. Vaccine. 2025. PMID: 41385808. doi:10.1016/j.vaccine.2025.128077
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。